Search | Page 6 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Effectiveness of lenalidomide in patients over 75 vs. patients under 75 with RBC transfusion-dependent low/int-1-risk MDS and del5q

    ... treatment affords many patients a sustained RBC transfusion independence and a significant cytogenetic response. ... neutrophil count) and thrombocytopenia (low platelet count).   These low blood counts can lead to infectious or ...

    Research Review last updated 05/02/2016 - 9:32am.

  2. Treatments

    ... A blood transfusion is a safe and common procedure. Most people who have a bone ... red blood cell , white blood cell or platelet counts. ...

    Topic section last updated 04/19/2016 - 3:36pm.

  3. More is better: Combination therapies for myelodysplastic syndromes

    ... MDS patients in an effort to reduce red blood cell transfusion dependence. -The current FDA approved agents have been tested with platelet boosting agents, such as romiplostim, in an effort to increase ...

    Research Review last updated 05/02/2016 - 9:14am.

  4. ASH 2012 - Reviewing MDS Progress from Research and Clinical Perspectives

    ... purpura (ITP). Patients with ITP have a low platelet count, not because of a bone marrow problem, but due to an ... earlier studied in patients with MDS who also have a low platelet count and in the largest study, it was found that romiplostin ... treated with romiplostin, based on prior platelet transfusion needs and blood levels of the hormone TPO. So just ...

    Interview last updated 02/07/2013 - 1:28pm.

  5. Myeloablative Unrelated Donor Cord Blood Transplantation With T-Cell Depleted Haplo-identical Peripheral Blood Stem Cells for Patients With High Risk Hematological Malignancies

    ... cytopenia (s), and/or red blood cell or platelet transfusion dependence, or patients with aplasia, or patients with excess ...

    Clinical Trial last updated 04/29/2016 - 1:33pm.

  6. Eltrombopag With Standard Immunosuppression for Severe Aplastic Anemia

    ... to a single course of ATG (non-robust responders), even when transfusion-independence is achieved, predicts a worse prognosis than when ... (TPO) is the principal endogenous regulator of platelet production. In addition, TPO also has stimulatory effects on more ...

    Clinical Trial last updated 04/25/2016 - 2:47pm.

  7. Safety and Effect of GL-ONC1 Administered IV With or Without Eculizumab Prior to Surgery to Patients With Solid Organ Cancers Undergoing Surgery

    ... ≥ 1.5 × 109; Platelets ≥ 100 × 109 (without platelet transfusion ); Hemoglobin ≥ 9.0 g/dL(with or without red ...

    Clinical Trial last updated 04/28/2016 - 1:57pm.

  8. A Phase I Study to Assess the Safety APL-2 as an Add-On to Standard of Care in Subjects With PNH

    ... Hb < 10 g/dL at screening OR have received at least one transfusion within 12 months prior to screening Platelet count of >30,000/mm3 Absolute neutrophil count > ...

    Clinical Trial last updated 08/24/2016 - 11:15am.

  9. A Phase I Study to Assess the Safety APL-2 as an Add-On to Standard of Care in Subjects with PNH

    ... Hb < 10 g/dL at screening OR have received at least one transfusion within 12 months prior to screening Platelet count of > 30,000/mm3 Absolute neutrophil ...

    Clinical Trial last updated 07/19/2016 - 12:46pm.

  10. Lower-Risk MDS: Diagnosis and Treatment Options

    ... neutrophil count less than 1,800/uL and platelet count less than 100,000/mm3. The second criterion is the ... cation–based Prognostic Scoring System (WPSS), which takes transfusion dependence into account, along with the three factors in the IPSS, ...

    Interview last updated 05/18/2012 - 1:28pm.